Atea Pharmaceuticals (AVIR) Q4 2024 earnings summary

Executive summary

• Advanced HCV program with bemnifosbuvir and ruzasvir, achieving 98% SVR12 in adherent patients in Phase 2 and preparing for global Phase 3 enrollment in April 2025 after a successful FDA meeting.

• Initiated cost-cutting actions, including a 20-25% workforce reduction, expected to save $15 million through 2027.

• Retained Evercore to explore strategic partnerships and appointed Arthur S. Kirsch as an independent director to enhance financial and strategic oversight.

Financial highlights

• Ended 2024 with $454.7 million in cash, cash equivalents, and marketable securities, down from $578.1 million at year-end 2023, with a projected cash runway into 2028.

• Net loss for 2024 was $168.4 million, compared to $135.1 million in 2023; net loss per share was $(2.00) versus $(1.63) in 2023.

• Operating expenses for 2024 were $193.0 million, up from $164.2 million in 2023, driven by increased R&D spending.

• R&D expenses increased due to higher external spend on HCV and COVID-19 trials; G&A expenses remained stable.

• Interest income declined year over year due to lower investment balances.

Outlook and guidance

• Global Phase 3 HCV program enrollment to begin in April 2025, targeting over 250 sites and 1,600 patients worldwide.

• Substantially all 2025 external R&D spend will focus on the Phase 3 HCV program.

• Additional Phase 2 data to be presented at EASL in May and at a scientific meeting in the first half of 2025.

• Continued focus on HCV program and strategic partnerships.